Chiranjib Chakraborty, Minna J. Hsu and Govindasamy Agoramoorthy Pages 864 - 876 ( 13 )
The type 2 diabetes or T2D mellitus has turn into an epidemic throughout the globe in recent years. Various forms of treatment modalities have been available for patients with T2D with some major classes of approved drugs that include Sulfonylureas, Meglitinides, Biguanides, Thiazolidinedione, Alpha-glucosidase inhibitors, GLP-1 analogs, DPP-4 Inhibitors, and SGLT2 inhibitors. This review focuses on the drug metabolizing enzymes (DME), gene polymorphisms, and inter-individual variability in therapeutics including adverse reaction effects involving Phase-I DME and Phase-II in general. This review also covers some key anti-diabetic drugs with respect to their pharcogenomics.
Asia, Diabetes, drugs, enzymes, pharcogenomics, T2D.
College of Pharmacy and Health Care, Tajen University, Yanpu, Pingtung 907, Taiwan.